TCF3 is an inclusion criterion in 33 clinical trials for acute lymphoblastic leukemia, of which 22 are open and 11 are closed. Of the trials that contain TCF3 status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 9 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 16 are phase 2 (11 open), and 3 are phase 3 (2 open) [4].

TCF3 is an inclusion criterion in 31 clinical trials for acute myeloid leukemia, of which 21 are open and 10 are closed. Of the trials that contain TCF3 status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 4 are phase 1/phase 2 (4 open), 16 are phase 2 (11 open), and 2 are phase 3 (1 open) [4].

TCF3 is an inclusion criterion in 28 clinical trials for myelodysplastic syndromes, of which 19 are open and 9 are closed. Of the trials that contain TCF3 status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (0 open), 8 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 15 are phase 2 (10 open), and 1 is phase 3 (1 open) [4].

TCF3 is an inclusion criterion in 19 clinical trials for chronic myeloid leukemia, of which 12 are open and 7 are closed. Of the trials that contain TCF3 status and chronic myeloid leukemia as inclusion criteria, 1 is early phase 1 (0 open), 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 10 are phase 2 (6 open) [4].

TCF3 is an inclusion criterion in 13 clinical trials for hodgkin lymphoma, of which 8 are open and 5 are closed. Of the trials that contain TCF3 status and hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 5 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open) [4].

TCF3 is an inclusion criterion in 10 clinical trials for non-hodgkin lymphoma, of which 6 are open and 4 are closed. Of the trials that contain TCF3 status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (4 open) [4].

TCF3 is an inclusion criterion in 9 clinical trials for acute biphenotypic leukemia, of which 5 are open and 4 are closed. Of the trials that contain TCF3 status and acute biphenotypic leukemia as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

TCF3 is an inclusion criterion in 9 clinical trials for Burkitt lymphoma, of which 4 are open and 5 are closed. Of the trials that contain TCF3 status and Burkitt lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

TCF3 is an inclusion criterion in 9 clinical trials for multiple myeloma, of which 7 are open and 2 are closed. Of the trials that contain TCF3 status and multiple myeloma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (3 open) [4].

TCF3 is an inclusion criterion in 8 clinical trials for mantle cell lymphoma, of which 4 are open and 4 are closed. Of the trials that contain TCF3 status and mantle cell lymphoma as inclusion criteria, 4 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 7 clinical trials for acute leukemia, of which 4 are open and 3 are closed. Of the trials that contain TCF3 status and acute leukemia as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

TCF3 is an inclusion criterion in 7 clinical trials for anaplastic large cell lymphoma, of which 4 are open and 3 are closed. Of the trials that contain TCF3 status and anaplastic large cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 7 clinical trials for chronic lymphocytic leukemia, of which 5 are open and 2 are closed. Of the trials that contain TCF3 status and chronic lymphocytic leukemia as inclusion criteria, 1 is early phase 1 (0 open), 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [4].

TCF3 is an inclusion criterion in 6 clinical trials for follicular lymphoma, of which 3 are open and 3 are closed. Of the trials that contain TCF3 status and follicular lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 6 clinical trials for lymphoma, of which 3 are open and 3 are closed. Of the trials that contain TCF3 status and lymphoma as inclusion criteria, 2 are phase 1 (0 open), 2 are phase 2 (2 open), and 2 are phase 3 (1 open) [4].

TCF3 is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 3 are open and 3 are closed. Of the trials that contain TCF3 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 5 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain TCF3 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [4].

TCF3 is an inclusion criterion in 5 clinical trials for myelofibrosis, of which 2 are open and 3 are closed. Of the trials that contain TCF3 status and myelofibrosis as inclusion criteria, 1 is early phase 1 (0 open), 2 are phase 1 (1 open), and 2 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 5 clinical trials for myeloproliferative neoplasm, of which 3 are open and 2 are closed. Of the trials that contain TCF3 status and myeloproliferative neoplasm as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

TCF3 is an inclusion criterion in 5 clinical trials for prolymphocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain TCF3 status and prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

TCF3 is an inclusion criterion in 4 clinical trials for acute undifferentiated leukemia, of which 3 are open and 1 is closed. Of the trials that contain TCF3 status and acute undifferentiated leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), and 1 is phase 3 (0 open) [4].

TCF3 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 2 are closed. Of the trials that contain TCF3 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 4 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain TCF3 status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 4 clinical trials for lymphoblastic lymphoma, of which 3 are open and 1 is closed. Of the trials that contain TCF3 status and lymphoblastic lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 0 are closed. Of the trials that contain TCF3 status and diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for lymphoplasmacytic lymphoma, of which 1 is open and 2 are closed. Of the trials that contain TCF3 status and lymphoplasmacytic lymphoma as inclusion criteria, 3 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for myelodysplastic/myeloproliferative neoplasm, of which 3 are open and 0 are closed. Of the trials that contain TCF3 status and myelodysplastic/myeloproliferative neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for plasma cell leukemia, of which 1 is open and 2 are closed. Of the trials that contain TCF3 status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for secondary acute myeloid leukemia, of which 3 are open and 0 are closed. Of the trials that contain TCF3 status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for T-cell lymphoblastic leukemia/lymphoma, of which 2 are open and 1 is closed. Of the trials that contain TCF3 status and T-cell lymphoblastic leukemia/lymphoma as inclusion criteria, 3 are phase 1 (2 open) [4].

TCF3 is an inclusion criterion in 3 clinical trials for therapy-related myelodysplastic syndrome, of which 3 are open and 0 are closed. Of the trials that contain TCF3 status and therapy-related myelodysplastic syndrome as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for acute erythroid leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3 status and acute erythroid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for acute megakaryoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3 status and acute megakaryoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for B-cell acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for B-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain TCF3 status and B-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for Burkitt leukemia, of which 2 are open and 0 are closed. Of the trials that contain TCF3 status and Burkitt leukemia as inclusion criteria, 2 are phase 1 (2 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for small lymphocytic lymphoma, of which 1 is open and 1 is closed. Of the trials that contain TCF3 status and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 2 clinical trials for T-cell prolymphocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain TCF3 status and T-cell prolymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for acute leukemia of ambiguous lineage, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and acute leukemia of ambiguous lineage as inclusion criteria, 1 is phase 2 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia arising from previous myelodysplastic syndrome, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and acute myeloid leukemia arising from previous myelodysplastic syndrome as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for adult T-cell leukemia/lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and adult T-cell leukemia/lymphoma as inclusion criteria, 1 is phase 3 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for aplastic anemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and aplastic anemia as inclusion criteria, 1 is phase 1 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for leukemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and mature T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-1, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and myelodysplastic syndrome with excess blasts-1 as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for myeloid sarcoma, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and myeloid sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for natural killer cell lymphoblastic leukemia/lymphoma, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and natural killer cell lymphoblastic leukemia/lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for plasma cell neoplasm, of which 0 are open and 1 is closed. Of the trial that contains TCF3 status and plasma cell neoplasm as inclusion criteria, 1 is phase 1 (0 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for refractory anemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and refractory anemia as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and refractory anemia with excess blasts as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for T-cell and NK-cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and T-cell and NK-cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

TCF3 is an inclusion criterion in 1 clinical trial for therapy-related chronic myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains TCF3 status and therapy-related chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].